Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate
2024 · Clinical Cancer Research · 10 citations
https://doi.org/10.1158/1078-0432.ccr-24-1779
N
Nikita Henning
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
30
Citations
3
h-index
2
i10-index
Nikita Henning is an academic researcher from University of Saskatchewan. The author has contributed to research in topics: Radiopharmaceutical Chemistry and Applications & HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 3, co-authored 46 publications.
Papers by this author
worksPreclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors
2024 · European Journal of Nuclear Medicine and Molecular Imaging · 2 citations
https://doi.org/10.1007/s00259-024-07011-2
[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer
2026 · Breast Cancer Research · 0 citations
https://doi.org/10.1186/s13058-026-02220-z
Additional file 1 of [225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer
2026 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.31311238
Additional file 1 of [225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer
2026 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.31311238.v1
[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer
2026 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.8302891.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat